key: cord-0835507-9gz4450f
authors: Buehler, P. K.; Zinkernagel, A. S.; Hofmaenner, D. A.; Wendel Garcia, P. D.; Acevedo, C. T.; Gomez-Mejia, A.; Mairpady Shambat, S.; Andreoni, F.; Maibach, M.; Bartussek, J.; Hilty, M.; Frey, P. M.; Schuepbach, R. A.; Brugger, S. D.
title: Bacterial pulmonary superinfections are associated with unfavourable outcomes in critically ill COVID-19 patients
date: 2020-09-11
journal: nan
DOI: 10.1101/2020.09.10.20191882
sha: 11229d4c488643113ba44eb124c265aea23a870a
doc_id: 835507
cord_uid: 9gz4450f

Objectives While superinfections are associated with unfavourable disease course, their impact on clinical outcomes in critically ill COVID-19 patients remains largely unknown. We aimed to investigate the burden of superinfections in COVID-19 patients. Methods In this prospective single centre cohort study in an intensive care setting patients aged [≥] 18 years with COVID-19 acute respiratory distress syndrome were assessed for concomitant microbial infections by longitudinal analysis of tracheobronchial secretions, bronchoalveolar lavages and blood. Our primary outcome was ventilator-free survival on day 28 in patients with and without clinically relevant superinfection. Further outcomes included the association of superinfection with ICU length of stay, incidence of bacteremia, viral reactivations, and fungal colonization. Results In 45 critically ill COVID-19 patients, we identified 19 patients with superinfections (42.2%) by longitudinal analysis of 433 TBS, 35 BAL and 455 blood samples, respectively. On average, superinfections were detected on day 10 after ICU admission. The most frequently isolated clinically relevant bacteria were Enterobacteriaceae, Streptococcus pneumoniae, and Pseudomonas aeruginosa. Ventilator-free survival was substantially lower in patients with superinfection (subhazard ratio 0.37, 95%-CI 0.15-0.90, p=0.028). Patients with pulmonary superinfections more often had bacteraemia, virus reactivations, yeast colonization, and needed ICU treatment for a significantly longer time. Conclusions The detection of superinfections was frequent and associated with reduced ventilator-free survival. Despite empirical antibiotic therapy, superinfections lead to an extended ICU stay in COVID 19 patients. Longitudinal microbiological sampling in COVID-19 patients could allow targeted antimicrobial therapy, and therefore minimize the use of broad-spectrum and reserve antibiotics.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evolved as the most 72 relevant pandemic of modern history, challenging health care systems all over the world. The was performed. The high mortality in severely ill COVID-19 patients is thought to be at least in 91 part due to secondary infections in addition to viral replication in the lower respiratory tract 92 leading to severe lung injury and ARDS (6, 13, 14). 93 Superinfection seems to represent a major risk factor for mortality in COVID-19 patients (7, 15-94 17). However, the risk of superinfection in mechanically ventilated patients with severe COVID-95 19 remains poorly described. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 11, 2020. . https://doi.org/10.1101/2020.09.10.20191882 doi: medRxiv preprint recommend longitudinal sampling of severely ill patients for early detection and treatment during 104 the entire course of the disease (6, 18).

Rapid diagnosis of co-and superinfection may not only help to improve survival but would also 107 allow targeted antimicrobial therapy, improving antimicrobial stewardship throughout the course 108 of the pandemic (18, 19).

The aim of our study was to assess the burden of superinfections and the association with clinical CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 11, 2020. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 11, 2020. . https://doi.org/10.1101/2020.09.10.20191882 doi: medRxiv preprint Consultants of the infectious disease department unrelated to the study group were involved 184 daily in the diagnosis and management of patients including specific antimicrobial treatment.

Organisms with low pathogenicity for lung infections such as Enterococcus spp., Candida spp., 186 coagulase-negative Staphylococci and non-pneumococcal Streptococci were reported but not 187 considered a relevant clinical pathogen of the airways in accordance with the literature (25).

Detection of the herpesviridae herpes simplex 1 and 2 as well as cytomegalovirus, Epstein-Barr 189 virus, human herpes virus 6 in blood were also reported but were considered to be reactivations. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 11, 2020. .

Cohort characteristics 208 A total of 48 critically ill COVID-19 patients with ARDS were screened in ICU at the University 209 Hospital Zurich between April and June 2020. Three patients had to be excluded from the (Table 1) . (Table 2) . Table 2 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 11, 2020. . 266 Patients with superinfections detected in respiratory specimens were ventilated for significantly 267 longer time periods (8 vs 37 days, p<0.001) and had a significantly longer duration of stay in the 268 ICU (9 vs 39 days, p<0.001) and overall hospitalization time (17 vs 44 days, p<0.001) as 269 compared to patients without superinfections (Table 2) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 11, 2020. . 357 All authors declare no conflicts of interest in this paper. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 11, 2020. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 11, 2020. .

Corman Streptococcus pneumoniae 0 (0%) 2 (0.5%) Burkholderia cepacia 0 (0%) 24 (6.5%) Morganella morganii 0 (0%) 2 (0.5%)

Overall relevant positive detection 2/152 (1.3%) 12/303 (4.0%) Citrobacter 0 (0%) 2 (16.7%) Enterococci faecalis and faecium 1 (50%) 6 (50%) Klebsiella aerogenes 0 (0%) 1 (8.3%) Klebsiella pneumonia 0 (0%) 1 (8.3%) Moraxella spp 1 (50%) 0 (0%) Candida glabrata 0 (0%) 1 (8.3%) Pseudomonas aeruginosa 0 (0%) 1 (8.3%)

Atypical pneumonia pathogens (n=35) 0 (0%) 1 (%) (Legionella)

Overall 2 9 Influenza A 0 (0%) 1 (11.1%) Influenza B 0 (0%) 0 (0%) Respiratory viruses block analysis (n=34) 0 (0%) 0 (0%) HSV 1 (PCR in blood) 0 (0%) 5 (55.5%) HSV 2 (PCR in blood) 0 (0%) 0 (0%) HHV6 (PCR in blood) 0 (0%) 2 (22.2%) CMV (PCR in blood) 1 (50%) 0 (0%) EBV (PCR in blood) 1 (50%) 1 (11.1%)

Assessed for eligibility (patients n=48) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 11, 2020. .

Baseline 374 Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the 375 Lombardy Region

Clinical features of patients infected with 377 2019 novel coronavirus in Wuhan

Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with 380 COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort

Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. 384 JAMA internal medicine

A Novel Coronavirus from Patients with 386 Pneumonia in China

Bacterial and 388 fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial 389 prescribing

Clinical course and risk factors for mortality of 391 adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Community-acquired respiratory coinfection in critically ill patients with pandemic 2009 influenza A(H1N1) 395 virus

Early bacterial co-infection in ARDS 397 related to COVID-19

Co-infections in people with COVID-19: a systematic 399 review and meta-analysis. The Journal of infection

Bacterial and fungal coinfection 401 among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. 402 Clinical Microbiology and Infection

Hazardous mismatch 404 between pulmonary pathogens and antibiotic treatments in COVID-19 patients. British journal of 405 anaesthesia

Clinical course and outcomes of critically ill 407 patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational 408 study

Therapeutic and triage strategies for 2019 410 novel coronavirus disease in fever clinics

Nosocomial infection among patients with COVID-19: 412 A retrospective data analysis of 918 cases from a single center in Wuhan, China. Infection control and 413 hospital epidemiology

Clinical predictors of mortality due to COVID-19 415 based on an analysis of data of 150 patients from Wuhan, China. Intensive care medicine

Epidemiological and clinical characteristics 417 of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study